SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC Keeping it real board for pro and con discussions
NNVC 1.680-8.7%Oct 30 3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Savant4/7/2020 12:35:02 PM
1 Recommendation

Recommended By
HardToFind

  Read Replies (1) of 326
 
the Japanese are in later-phase trials of a drug which has reportedly shown promise. Favipiravir, manufactured by Fujifilm Toyama Chemical, has been used in China, with the Chinese officials – not normally prone to promoting Japan – stating that the antiviral drug is acting on the novel coronavirus in the way it has acted on other viruses, which is to say it is dramatically reducing the severity and duration of symptoms. The Chinese medical community tests demonstrated that treatment with the drug reduced average infection time following diagnosis from eleven days to four.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News